HER2-targeted therapy influences CTC status in metastatic breast cancer

• DOI: 10.1007/s10549-020-05687-2
• Publication Date: 2020-05-20T18:04:11Z
• Authors: Thomas M. Deutsch; Sabine Riethdorf; Carlo Fremd; Manuel Feisst; Juliane Nees; Chiara Fischer; Andreas D. Hartkopf; Klaus Pantel; Andreas Trumpp; Florian Schütz; Andreas Schneeweiss; Markus Wallwiener
• Keywords: Lapatinib; Pertuzumab; Circulating tumor cell; Targeted Therapy; Liquid biopsy

Abstract Purpose As an independent, negative-prognostic biomarker for progression-free survival (PFS) and overall (OS), circulating tumor cells (CTCs) constitute a promising component developing liquid biopsy patients with metastatic breast cancer (MBC). The effects of HER2-targeted therapy such as trastuzumab, pertuzumab, T-DM1, lapatinib on CTC status longitudinal enumeration were assessed in this trial. Methods 264 MBC was analyzed prior to after 4 weeks new line palliative systemic therapy. CTCs using CellSearch®. Three groups compared: HER2-positive receiving ongoing ( n = 28), de novo no the last 12 months enrollment start 15), HER2-nonamplified disease 212). Results Positive (≥ 5 CTC/7.5 ml blood) at observed 3 17.9, 46.7, 46.2% p 0.02) patients, respectively. At least one seen 28.6, 53.3, 67.0% < 0.001) these patients. Furthermore, 3.6, 40.0, 3.3% had CTC. After 7.1, 0.0, 31.1% still positive blood). 25.0, 20.0, 50.5% 0.004) 1.9% 0.187) therapy, 35.7, 28.3% 0.536) showed progression. Conclusions seems reduce count MBC. This should be taken into account when is used indicator aggressive or indolent disease.